8.3 Palliative Care Integration, Advance Directives & Ethical Considerations
Key Takeaways
- Palliative care can accompany curative or life-prolonging HCT/cellular therapy at any stage, addressing symptoms, coping, communication and goals; randomized HCT trials support early integration without evidence of survival harm.
- Hospice is a prognosis- and benefit-defined model. Under the U.S. Medicare benefit, patients generally elect comfort-focused care for the terminal diagnosis, but symptom-directed transfusions or disease-modifying treatment may be covered when part of the hospice plan.
- Advance-care planning is iterative. Surrogate instruments, advance directives and POLST/MOLST rules vary by jurisdiction and document and should be completed before crisis when possible.
- Living donors require voluntary informed consent, privacy, independent advocacy/evaluation and a clear withdrawal process, with counseling about the grave timing implications once recipient conditioning begins.
- Minor donors require parental permission, developmentally appropriate assent/dissent attention, independent donor advocacy and pediatric collection expertise under current standards and law.
Palliative Care, Advance Care Planning and Ethics
Clinical principle: Palliative care adds symptom, coping, communication and decision support alongside disease-directed care. Ethical HCT/cellular therapy protects patient and donor autonomy, benefit, safety, justice and privacy while recognizing uncertainty and jurisdiction-specific law.
1. Integrated Palliative Care
Palliative care can begin at diagnosis, transplant evaluation, admission, toxicity, relapse or survivorship and does not require stopping curative therapy. Randomized inpatient HCT studies found improved quality of life, symptom burden and mood during hospitalization and some later psychological outcomes, without evidence of worse survival. These results support early access; they do not require the same consultation schedule for every patient.
The team treats pain, nausea, mucositis, dyspnea, fatigue, diarrhea, sleep and anxiety; clarifies illness understanding and prognosis; supports family/caregivers and spirituality; and explores what outcomes and tradeoffs matter. Goals-of-care conversations recur when disease, toxicity or function changes. A framework such as REMAP—reframe, expect emotion, map values, align, propose a plan—can structure a recommendation without shifting decisions onto the family.
2. Palliative Care and Hospice
Palliative care is based on need and can accompany chemotherapy, HCT, cellular therapy, ICU care, dialysis and transfusion. Hospice in the United States generally requires physician certification of a prognosis of about six months if illness follows its usual course and election of a hospice benefit. Under Medicare, the election waives ordinary Medicare payment for treatment directed at the terminal illness outside the hospice arrangement, but hospice plans can include palliative disease-directed treatment or transfusion when the hospice agrees it serves comfort and can provide it. Coverage and services vary; avoid promising that all transfusions continue or asserting that every disease-directed therapy must stop.
At end of life, discontinue or continue tests, nutrition, antimicrobials, transfusions, ventilation and dialysis according to goals, expected benefit/burden and the agreed plan. Palliative sedation is a specialist, ethics- and policy-governed option for otherwise refractory suffering—not routine medication escalation—and requires proportional dosing, consent/surrogate process and ongoing comfort care.
3. Advance Care Planning and Capacity
Advance care planning documents values, acceptable outcomes, a chosen surrogate and preferences for future care. A health-care power of attorney/proxy designates a surrogate; when authority begins depends on state law and the document. A living will records treatment preferences. POLST/MOLST converts current preferences for seriously ill patients into portable medical orders; eligibility, signer and scope vary by jurisdiction. These instruments complement, rather than replace, contemporaneous informed consent and capacity assessment.
Ask the patient directly while capacity is intact, use qualified interpreters and revisit choices. If capacity is lost, the legally authorized surrogate applies known wishes or substituted judgment, with best-interest standards when wishes are unknown. Nurses verify the applicable document/order, communicate changes, prevent unwanted treatment when safely possible and involve ethics/legal resources for conflict.
4. Living-Donor Ethics
A healthy donor assumes risk without direct therapeutic benefit. Evaluation and consent must be donor-centered, confidential and sufficiently independent from recipient pressure. Explain mobilization/collection options, common and serious risks, alternatives, privacy, expenses, follow-up and the right to decline. The donor can withdraw, and counseling should explain that withdrawal after recipient conditioning may leave the recipient without a restorative graft and cause grave harm; concerns should be raised early through the independent donor team. Communicate only the donor information authorized by consent and policy—do not invent a false diagnosis to conceal refusal.
For a minor donor, the legal guardian provides permission and the team seeks developmentally appropriate assent, attends seriously to dissent and uses an independent donor advocate or advocacy team without responsibility for the recipient. The advocate focuses on the child's interests, coercion, understanding and follow-up. Pediatric-trained collection/anesthesia staff and blood-volume, access, pain and psychosocial safeguards are required by the applicable standards and law.
5. Justice and Access
Cellular therapies can impose insurance, travel, lodging, caregiver, language and manufacturing barriers. Use transparent clinical criteria, conflict-of-interest controls and an appeal process for scarce slots; never rank social worth, wealth, language or perceived deservingness. Provide navigation and reasonable accommodations before interpreting a logistical barrier as nonadherence. Discuss alternatives, clinical trials, palliative options and costs honestly without coercion. When conflict persists, name the disagreement, confirm capacity and representation, use time-limited trials when appropriate, and engage ethics, social work, spiritual care, risk management or legal counsel according to the issue. Document the patient’s values, the clinical recommendation, participants, uncertainty, and follow-up trigger so decisions remain understandable across settings and shifts. After death or treatment discontinuation, provide family bereavement resources and staff debriefing while protecting confidentiality.
6. End-of-Life Care in Transplant and Cellular Therapy
The blueprint names end-of-life care, including hospice and legacy building, as an explicit element, and transplant populations reach it along a distinctive path: many patients transition from a curative-intent, highly technical course into the final weeks very quickly, sometimes while still receiving transplant-directed therapy.
Transitions are often compressed. Referral to hospice frequently happens late in this population because the treatment trajectory encourages continued escalation. Introducing hospice as an additional layer of support rather than as a decision to stop makes the conversation possible earlier.
Transfusion is the recurring dilemma. Platelet and red cell support may relieve symptoms and hold real meaning for patients and families, yet many hospice arrangements do not readily provide it. Address the question explicitly during transition planning rather than allowing it to surface as a crisis after enrollment.
Legacy building is an intervention, not a sentiment. Recorded messages, letters, handprints, memory books, and structured life review are offered proactively and can be led by nursing, child life, social work, or chaplaincy. Offer early, when the patient still has the energy to participate meaningfully.
Bereavement support extends to staff. Transplant teams form long relationships with patients across months of intensive care, and programs that provide structured debriefing and remembrance for staff sustain the workforce that delivers this care.
Which statement accurately summarizes the clinical evidence established by randomized controlled trials (such as the landmark El-Jawahri trials) regarding early integrated palliative care for patients undergoing hematopoietic cell transplantation?
An 8-year-old is a potential marrow donor for a sibling. Which safeguard best reflects current pediatric donor ethics and FACT-JACIE principles?
A 62-year-old patient who is 18 days post-allogeneic HCT develops severe septic shock, acute respiratory distress syndrome requiring mechanical ventilation, and worsening acute kidney injury on continuous renal replacement therapy (CRRT). Prior to admission, the patient completed a valid Healthcare Proxy naming their spouse as the healthcare surrogate and completed a Living Will stating a desire to avoid prolonged mechanical life support if recovery is impossible. The transplant team determines multiorgan failure is irreversible. When conducting a goals-of-care conference with the spouse, which communication approach is most appropriate?